Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
295.27
+0.65 (0.22%)
At close: Oct 9, 2025, 4:00 PM EDT
295.59
+0.32 (0.11%)
After-hours: Oct 9, 2025, 4:04 PM EDT
Amgen Revenue
Amgen had revenue of $9.18B in the quarter ending June 30, 2025, with 9.43% growth. This brings the company's revenue in the last twelve months to $34.92B, up 12.88% year-over-year. In the year 2024, Amgen had annual revenue of $33.42B with 18.57% growth.
Revenue (ttm)
$34.92B
Revenue Growth
+12.88%
P/S Ratio
4.54
Revenue / Employee
$1,247,036
Employees
28,000
Market Cap
158.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33.42B | 5.23B | 18.57% |
| Dec 31, 2023 | 28.19B | 1.87B | 7.09% |
| Dec 31, 2022 | 26.32B | 344.00M | 1.32% |
| Dec 31, 2021 | 25.98B | 555.00M | 2.18% |
| Dec 31, 2020 | 25.42B | 2.06B | 8.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AMGN News
- 2 days ago - Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers - CNBC
- 3 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 3 days ago - Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts - WSJ
- 3 days ago - Amgen to sell cholesterol drug at 60% discount direct to US consumers - Reuters
- 3 days ago - AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S. - PRNewsWire
- 5 days ago - October Dogs Of The Dow Flash One Ideal 'Safer' Dividend Buy - Seeking Alpha
- 7 days ago - LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS - PRNewsWire
- 8 days ago - Amgen Shares Cross Above 200 DMA - Forbes